Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257]

Citation

Zheng Xue, Xie Jizhen, Zhang Xing, Sun Weiting, Zhao Heyang, Li Yantuan, Wang Cheng. Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257][J]. Chin. Chem. Lett., 2025, 36(2): 110545

Xue Zheng^a, Jizhen Xie^c, Xing Zhang^a, Weiting Sun^a, Heyang Zhao^a, Yantuan Li^a,b^,*, Cheng Wang^a,b^,*

^a Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China;
^b Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China;
^c Shandong Center for Food and Drug Evaluation and Certification, Ji'nan 250013, China

Available online 16 November 2024

DOI of original article: 10.1016/j.cclet.2020.11.029
^* Corresponding authors at: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
E-mail addresses: yantuanli@ouc.edu.cn (Y. Li), cheng13980029671@163.com (C. Wang).

The authors regret <According to ref. [90], the sentence on page 249 "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in Taiwan and Singapore (n = 22) [90]." should be revised to "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in the United States and Europe (n = 22) [90].">.

The authors would like to apologise for any inconvenience caused.